Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Researchers found a lack of promising investigational treatments in late-stage development for SCLC in the second-line setting and beyond.
Carboplatin and cisplatin are interchangeable in patients with limited-stage small-cell lung cancer undergoing chemoradiation, a real-world study suggests.
Adding serplulimab to chemotherapy prolonged overall survival in patients with previously untreated, extensive-stage small cell lung cancer.
An estimated 3% to 6% of patients with limited-stage small-cell lung cancer develop grade 3-5 pneumonitis after concurrent chemoradiation.
Survival outcomes for SCLC patients with brain metastases appear comparable with stereotactic radiosurgery and whole brain radiotherapy.
Serplulimab improved overall survival, progression-free survival, and duration of response.
Adding tiragolumab to a 3-drug regimen did not improve progression-free or overall survival.
Adding adebrelimab to chemotherapy nearly doubled the 2-year overall survival rate and more than tripled the 1-year progression-free survival rate.
A greater likelihood of socioeconomic disadvantages may help explain the poor survival outcomes observed in patients with small-cell lung cancer, according to researchers.